84% of patients prefer Novo Nordisk’s oral Wegovy over Lilly’s pill, with 14x lower dropout rate. Phase 3 trial shows 21.6% weight loss and Medicare access at $50 copay by 2026.<\/p>\n
Nearly nine in ten patients surveyed favor Novo Nordisk’s oral version of Wegovy over a rival’s experimental pill, a finding that could reshape the obesity treatment landscape. On the sidelines of the European Congress on Obesity in Istanbul, the Danish drugmaker released a flurry of clinical updates that collectively bolster the case for a tablet-based semaglutide therapy. The 84 percent preference figure emerged from the OPTIC study, where participants compared the tolerability profile of Novo Nordisk’s oral candidate to Eli Lilly’s orforglipron. According to the ORION comparative analysis, the dropout rate from gastrointestinal side effects was roughly fourteen times lower for the Novo pill \u2014 a critical advantage in a market where compliance determines long-term success.<\/p>\n
Beyond tolerability, the company detailed robust weight-loss results from the OASIS 4 phase 3 trial. Nearly a third of adult patients responded early, shedding 13.2 percent of their body weight within sixteen weeks. By the study’s end, that figure climbed to 21.6 percent, underscoring the therapy’s ability to deliver sustained reductions. The benefits extended beyond the scale: eight out of ten patients who started with physical limitations doubled their mobility, making everyday tasks such as bending and prolonged standing noticeably easier. Novo also presented data on the 7.2-milligram dose from the STEP UP program, where MRI scans showed that 84 percent of lost weight came from fat mass. Visceral belly fat dropped by more than 30 percent, while muscle mass was largely preserved \u2014 a crucial metric as physicians increasingly scrutinize the composition of GLP-1-induced weight loss.<\/p>\n
The drugmaker also highlighted effects across the menopause spectrum. In a dedicated analysis, oral Wegovy produced significant weight reductions in women at all stages of menopause, alongside preliminary signals of cardiovascular protection and fewer migraine attacks. While these observations require further validation, they hint at expanding the medical utility of semaglutide beyond obesity alone.<\/p>\n